“Yeah, the good and the bad of having work done by an
“Yeah, the good and the bad of having work done by an independent researcher, good being independent, bad being they don't want all the data given in press releases until they publish.“
Ah, this explains why the PR on NASH is so vague. I’d really like to see the exact data, but then again, if CYDY can share it with potential partners, that’s all that matters.
Question: does anyone know how long the average NASH trial is? I’m assuming it may take a few years to get full results and that’s why NP is looking to partner.
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Russel Metals Inc. Reports Third Quarter Results for 2025 Russel Metals Inc. (TSX:RUS) has recently shared its financial performance for the three-month period ending September 30, 2025. The results reflect a positive trajectory in revenue and strategic initiatives to enhance its market position. Key Financial Metrics Overview In this quarter, Russel Metals has...
Continue Reading
KBC Group's Capital Position Remains Strong KBC Group has reported a robust standing in its capital levels, significantly exceeding the minimum capital requirements mandated by the European Central Bank (ECB). As part of the Supervisory Review and Evaluation Process (SREP) scheduled for the upcoming year, KBC received formal notification regarding its capital metrics....
Continue Reading
Synlogic Provides Third Quarter 2024 Financial Results Synlogic, Inc. (NASDAQ: SYBX), a prominent biopharmaceutical firm dedicated to developing innovative therapeutics for serious diseases, has recently outlined its financial performance for the third quarter of 2024. The organization is actively working on advancing its mission to enhance healthcare through...
Continue Reading
Incannex Healthcare's Remarkable Financial Progress Incannex Healthcare Inc. (NASDAQ: IXHL) is making impressive strides in the biopharmaceutical world, focusing on breakthrough treatments for chronic diseases. Their recent fiscal year report outlines not only financial outcomes but also a plethora of operational and clinical advancements aimed at addressing significant...
Continue Reading
Alpha Liquid Terminal Introduces ChatAnalyst Financial Agent Recently, a game-changing tool was launched that promises to redefine how individuals manage and interpret financial data. This is powered by the innovative company, Alpha Liquid Terminal. The newly unveiled AI-driven financial analyst agent, known as ChatAnalyst, is designed to simplify and streamline financial...
Continue Reading
